Human cytomegalovirus neutralizing antibodies and use thereof
AssigneeInstitute of Research in Biomedicine
InventorsAntonio Lanzavecchia, Annalisa Macagno
Life of this patent
Estimating the term…
Abstract
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
Claims28
An antibody, or antigen binding fragment thereof, comprising the CDR1, CDR2, and CDR3 sequences of the heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 242 and 243, respectively, wherein the antibody or antigen binding fragment thereof is produced by a CHO cell.
A host cell comprising a vector which comprises one or more nucleic acid molecules encoding the variable regions of an antibody, or antigen binding fragment thereof, comprising heavy and light chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 232, 233, and 234, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 235, 149, and 236, respectively, wherein the host cell is a hamster cell, a murine cell, or a rat cell.
A composition comprising an isolated antibody, or an antigen binding fragment thereof, comprising the CDR1, CDR2, and CDR3 sequences of the heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 242 and 243, respectively, wherein the composition is in lyophilized form.
Dependencies are inferred from the claim text.